Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082082 · ClinicalTrials.gov registry record · Phase 2
A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma
A Phase 2 study, sponsored by SciClone Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00082082 is a Phase 2 study that has completed, run by SciClone Pharmaceuticals.
The verdict
NCT00082082, a Phase 2 study, has completed, sponsored by SciClone Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The objective of this Phase II trial is to compare the efficacy and safety of 6 months of treatment with thymalfasin plus trans arterial chemoembolization (TACE) with TACE alone in adult patients with non-surgical hepatocellular carcinoma (HCC).
Interventions
- DRUG Thymalfasin (thymosin alpha-1)
- PROCEDURE Trans arterial chemoembolization (TACE)
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082082
The ClinicalTrials.gov registry entry for NCT00082082 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is SciClone Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Thymalfasin (thymosin alpha-1) is the first listed.
NCT00082082 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00082082 about?
NCT00082082 is a clinical study titled "A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma". The objective of this Phase II trial is to compare the efficacy and safety of 6 months of treatment with thymalfasin plus trans arterial chemoembolization (TACE) with TACE alone in adult patients with non-surgical hepatocellular carcinoma (HCC).
What is the current status of trial NCT00082082?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00082082?
The interventions under investigation include: Thymalfasin (thymosin alpha-1) (DRUG), Trans arterial chemoembolization (TACE) (PROCEDURE).
Who is sponsoring clinical trial NCT00082082?
This trial is sponsored by SciClone Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.